Apoe ε2 and ε4 influence the susceptibility for Alzheimer's disease but not other dementias

International Journal of Molecular Epidemiology and Genetics

Volumn 1, Issue 3, 2010, Pages 193-200

  Lovati, Carlo ^a   Galimberti, Daniela ^b   Albani, Diego ^c   Bertora, Pierluigi ^a   Venturelli, Eliana ^b   Cislaghi, Giuliana ^a   Guidi, Ilaria ^b   Fenoglio, Chiara ^b   Cortini, Francesca ^b   Clerici, Francesca ^a   Finazzi, Dario ^d   Forloni, Gianluigi ^c   Scarpini, Elio ^b   Mariani, Claudio ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Alzheimer's disease (AD); Apolipoprotein E (APOE); Frontotemporal lobar degeneraton (FTLD); Lewy body dementia (LBD); Risk factor; Vascular dementia (VaD)

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E4;

AGED; ALZHEIMER DISEASE; ARTICLE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FEMALE; FRONTOTEMPORAL DEMENTIA; GENE FREQUENCY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; RISK FACTOR;

EID: 77955681224     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923.
2. Boyles JK, Zoellner CD, Anderson LJ, Kosik LM, Pitas RE, Weisgraber KH, Hui II DY, Mahley RW, Gebicke-Haerter PJ, Ignatius MJ. A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest 1989; 83: 1015-1031.
3. Ignatius MJ, Shooter EM, Pitas RE, Mahley RW. Lipoprotein uptake by neuronal growth cones in vitro. Science 1987; 236: 959-962.
4. Poirier J, Baccichet A, Dea D, Gauthier S. Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience 1993; 55: 81-90.
5. Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC; Cache County Study Investigators. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Arch Gen Psychiatry 2004; 61: 518-524.
6. Myers RH, Schaefer EJ, Wilson PW, D'Agostino R, Ordovas JM, Espino A, Au R, White RF, Knoefel JE, Cobb JL, McNulty KA, Beiser A, Wolf PA. Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. Neurology 1996; 46: 673-677.
7. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993; 11: 575-580.
8. Saunders AM. Apolipoprotein E and Alzheimer disease: an update on genetic and functional anayses. J Neuropathol Exp Neurol 2000; 59: 751-758.
9. Saunders AM, Schmader K, Breitner JC, Benson MD, Brown WT, Goldfarb L, Goldgaber D, Manwaring MG, Szymanski MH, McCown N. Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 1993; 342: 710-711.
10. Scott J. Apolipoprotein E and Alzheimer's disease. Lancet 1993; 342: 696.
11. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's disease. Annual Rev Neurosci 1996, 19: 53-77.
12. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994; 7: 180-184.
13. Berlau DJ, Corrada MM, Head E, Kawas CH. APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology. 2009; 72:829-34.
14. Borenstein AR, Mortimer JA, Ding D, Schellenberg GD, Decarli C, Zhao Q, Copenhaver C, Guo Q, Chu S, Galasko D, Salmon DP, Dai Q, Wu Y, Petersen R, Hong Z. Effects of Apolipoprotein E-E4 and -E2 in Amnestic Mild Cognitive Impairment and Dementia in Shanghai: SCOBHI-P. Am J Alzheimers Dis Other Demen. 2010 Feb 8. [Epub ahead of print]
15. Ignatov I, Belden C, Jacobson S, Connor D, Sabbagh MN. Possible Alzheimer's disease in an apolipoprotein E2 homozygote. J Alzheimers Dis. 2009 Jan;16(1):35-8.
16. Tiraboschi P, Hansen LA, Masliah E, Alford M, Thal LJ, Corey-Bloom J. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 2004; 62: 1977-1983.
17. Aleshkov S, Abraham CR, Zannis VI. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. Biochemistry 1997; 36:10571-10580.
18. Maezawa I, Jin LW, Woltjer RL, Maeda N, Martin GM, Montine TJ, Montine KS. Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicity. J Neurochem 2004; 91: 1312-1321.
19. Bernardi L, Maletta RG, Tomaino C, Smirne N, Di Natale M, Perri M, Longo T, Colao R, Curcio SA, Puccio G, Mirabelli M, Kawarai T, Rogaeva E, St George Hyslop PH, Passarino G, De Benedictis G, Bruni AC. The effects of APOE and tau gene variability on risk of frontotemporal dementia. Neurobiol Aging 2006; 27: 702-709.
20. Gustafson L, Abrahamson M, Grubb A, Nilsson K, Fex G. Apolipoprotein-E genotyping in Alzheimer's disease and frontotemporal dementia. Dement Geriatr Cogn Disord 1997; 8: 240-243.
21. Geschwind D, Karrim J, Nelson SF, Miller B. The apolipoprotein E epsilon4 allele is not a significant risk factor for frontotemporal dementia. Ann Neurol 1998; 44: 134-138.
22. Short RA, Graff-Radford NR, Adamson J, Baker M, Hutton M. Differences in tau and apolipoprotein E polymorphism frequencies in sporadic frontotemporal lobar degeneration syndromes. Arch Neurol 2002; 59: 611-615.
23. Srinivasan R, Davidson Y, Gibbons L, Payton A, Richardson AM, Varma A, Julien C, Stopford C, Thompson J, Horan MA, Pendleton N, Pickering-Brown SM, Neary D, Snowden JS, Mann DM. The apolipoprotein E epsilon4 allele selectively increases the risk of frontotemporal lobar degeneration in males. J Neurol Neurosurg Psychiatry 2006; 77: 154-158.
24. Engelborghs S, Dermaut B, Goeman J, Saerens J, Marien P, Pickut BA, Van den Broeck M, Serneels S, Cruts M, Van Broeckhoven C, De Deyn PP. Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects. J Neurol Neurosurg Psychiatry 2003; 74: 1148-1151.
25. Verpillat P, Camuzat A, Hannequin D, Thomas-Anterion C, Puel M, Belliard S, Dubois B, Didic M, Lacomblez L, Moreaud O, Golfier V, Campion D, Brice A, Clerget-Darpoux F. Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis. Eur J Hum Genet 2002, 10: 399-405.
26. Baum L, Lam LC, Kwok T, Lee J, Chiu HF, Mok VC, Wong A, Chen X, Cheung WS, Pang CP, Ma SL, Tang NL, Wong KS, Ng HK. Apolipoprotein E epsilon4 allele is associated with vascular dementia. Dement Geriatr Cogn Disord 2006; 22: 301-305.
27. Davidson Y, Gibbons L, Purandare N, Byrne J, Hardicre J, Wren J, Payton A, Pendleton N, Horan M, Burns A, Mann DM. Apolipoprotein E epsilon4 allele frequency in vascular dementia. Dement Geriatr Cogn Disord 2006; 22: 15-19.
28. Treves TA, Bornstein NM, Chapman J, Klimovitzki S, Verchovsky R, Asherov A, Veshchev IO, Korczyn AD. APOE-e4 in patients with Alzheimer's disease and vascular dementias. Alzheimer Dis Assoc Disord 1996; 10: 189-191.
29. Frank A, Diez-Tejedor E, Bullido MJ, Valdivieso F, Barreiro P. APOE genotype in cerebrovascular disease and vascular dementia. J Neurol Sci 2002; 203-204: 173-176.
30. Guidi I, Galimberti D, Lonati S, Novembrino C, Bamonti F, Tiriticco M, Fenoglio C, Venturelli E, Baron P, Bresolin N, Scarpini E. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2006, 27: 262-269.
31. Traykov L, Rigaud AS, Baudic S, Smagghe A, Boller F, Forette F. Apolipoprotein E e4 allele frequency in demented and cognitively impaired patients with and without cerebrovascular disease. J Neurol Sci 2002; 203-204: 177-181.
32. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
33. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF. Frontotemporal lobar degeneration. A consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-1554.
34. McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 1999; 53: 902-905.
35. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250-260.
36. Del Bo R, Comi GP, Bresolin N, Castelli E, Conti E, Degiuli A, Ausenda CD, Scarlato G. The apolipoprotein E e4 allele causes a faster decline of cognitive performances in Down's syndrome subjects. J Neurol Sci 1997; 145: 87-91.
37. Nielsen AS, Ravid R, Kamphorst W, Jorgensen OS. Apolipoprotein E epsilon 4 in an autopsy series of various dementing disorders. J Alzheimer Dis 2003; 5: 119-125.
38. Singleton AB, Wharton A, O'Brien KK, Walker MP, McKeith IG, Ballard CG, O'Brien J, Perry RH, Ince PG, Edwardson JA, Morris CM. Clinical and neuropathological correlates of apolipoprotein E genotype in dementia with lewy bodies. Dement Geriatr Cogn Disord 2002; 14: 167-175.
39. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006; 9(Suppl 3): 417-423.
40. Guidi I, Galimberti D, Venturelli E, Lovati C, Del Bo R, Fenoglio C, Gatti A, Dominici R, Galbiati S, Virgilio R, Pomati S, Comi GP, Mariani C, Forloni G, Bresolin N, Scarpini E. Influence of the Glu298Asp polymorphism of NOS3 on age at onset and homocysteine levels in AD patients. Neurobiol Aging 2005; 26: 789-794.
41. Jellinger KA. The enigma of mixed dementia. Alzheimer's & Dementia 2007; 3: 40-53.
42. Stratman NC, Castle CK, Taylor BM, Epps DE, Melchior GW, Carter DB. Isoform-specific interactions of human apolipoprotein E to an intermediate conformation of human Alzheimer amyloid beta peptide. Chem Phys Lipids 2005; 137: 52-61.
43. Gearing M, Schneider JA, Robbins RS, Hollister RD, Mori H, Games D, Hyman BT, Mirra SS. Regional variation in the distribution of apolipoprotein E and A beta in Alzheimer's disease. J Neuropathol Exp Neurol 1995; 54: 833-841.
44. McNamara MJ, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype and deposits of Abeta40 and Abeta42 in Alzheimer disease. Arch Neurol 1998; 55: 1001-1004.
45. Scarpini E, Galimberti D, Bresolin N. Genetics and neurobiology of frontotemporal lobar degeneration. Neurol Sci 2006; 27 (Suppl 1): S32-34.
46. Scarpini E, Galimberti D, Guidi I, Bresolin N, Scheltens P. Progressive, isolated language disturbance: its significance in a 65-year-old-man. A case report with implications for treatment and review of literature. J Neurol Sci 2006; 240: 45-51.